Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Revenue   $ 3,762   $ 9,550
Operating expenses:        
Research and development $ 20,527 28,280 $ 67,134 86,650
General and administrative 5,655 7,764 17,383 22,394
Restructuring (See Note 12)   2,354   2,354
Total operating expenses 26,182 38,398 84,517 111,398
Loss from operations (26,182) (34,636) (84,517) (101,848)
Interest income 793 1,633 3,424 5,533
Interest expense (1,312) (1,303) (4,001) (3,798)
Change in fair value of warrant liabilities 20,305 (5,837) 51,663 (77)
Net loss applicable to common stockholders $ (6,396) $ (40,143) $ (33,431) $ (100,190)
Net loss per share applicable to common stockholders - basic $ (0.16) $ (1.43) $ (0.85) $ (3.59)
Net loss per share applicable to common stockholders - diluted $ (0.16) $ (1.43) $ (0.85) $ (3.59)
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic 39,335,772 27,990,558 39,194,933 27,915,951
Weighted-average number of common shares used in net loss per share applicable to common stockholders - diluted 39,335,772 27,990,558 39,194,933 27,915,951